SCHEMBL31358799

SCHEMBL31358799

O=C1C(=Cc2ccc(-c3ccc([N+](=O)[O-])cc3Cl)o2)C(=O)c2ccccc21

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.66
MEN1 O00255 9/20 0.66
MAPT P10636 9/20 0.66
POLB P06746 8/20 0.66
ALDH1A1 P00352 5/20 0.66
L3MBTL1 Q9Y468 6/20 0.52
NPSR1 Q6W5P4 4/20 0.52
MAPK1 P28482 2/20 0.52
PTPN5 P54829 2/20 0.49
PPM1G O15355 1/20 0.49
PTPN1 P18031 1/20 0.49
PTPN7 P35236 1/20 0.49
PTPRO Q16827 1/20 0.49
PTPN22 Q9Y2R2 1/20 0.49
GSK3A P49840 1/20 0.48
GSK3B P49841 1/20 0.48
KDM4E B2RXH2 4/20 0.48
PKM P14618 4/20 0.48
MCL1 Q07820 4/20 0.48
LMNA P02545 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31358883 0.91 GSK3A (0.59) KMT2AMEN1MAPTPOLBALDH1A1
SCHEMBL31358762 0.86 PIK3CG (0.60) KMT2AMEN1MAPTPOLBALDH1A1
SCHEMBL31358711 0.84 MAPT (0.64) KMT2AMEN1MAPTPOLBALDH1A1
SCHEMBL31358853 0.84 MAPT (0.60) KMT2AMEN1MAPTPOLBALDH1A1
SCHEMBL31358851 0.83 KMT2A (0.59) KMT2AMEN1MAPTPOLBALDH1A1
SCHEMBL31358671 0.83 MEN1 (0.58) KMT2AMEN1MAPTPOLBALDH1A1
SCHEMBL6391067 0.83 KMT2A (0.66) KMT2AMEN1MAPTPOLBALDH1A1
SCHEMBL31358707 0.83 MAPT (0.65) KMT2AMEN1MAPTPOLBALDH1A1
SCHEMBL31358680 0.81 KMT2A (0.58) KMT2AMEN1MAPTPOLBALDH1A1
SCHEMBL31358774 0.81 BRAF (0.67) KMT2AMEN1MAPTPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF PTPN18, PTPN7, PTPN1 KMT2A 1043/4885MEN1 2467/4885MAPT 4688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.